A NEW ERA OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITION IN CHOLANGIOCARCINOMA

被引：2
作者：
Lamarca, A. [1 ,2 ]
Moreno, V. [3 ]
Gambardella, V. [4 ,5 ]
Cervantes, A. [4 ,5 ]
机构：
[1] Fdn Jimenez Diaz Univ Hosp, Oncohealth Inst, Dept Med Oncol, Madrid, Spain
[2] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England
[3] Fdn Jimenez Diaz Univ Hosp, Dept Med Oncol, START FJD Phase Unit 1, Madrid, Spain
[4] Univ Valencia, Hosp Clin Univ, INCLIVA Biomed Res Inst, Valencia, Spain
[5] Inst Salud Carlos III, CIBERONC, Madrid, Spain
来源：
ESMO OPEN | 2023年 / 8卷 / 06期
关键词：
METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; EFFICACY;
D O I：
10.1016/j.esmoop.2023.102032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
    Wang, Dan
    Yang, Li
    Yu, Weina
    Zhang, Yi
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (10) : 903 - 916
  • [42] Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib
    Hakozaki, Taiki
    Okuma, Yusuke
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 (07) : 2664 - 2668
  • [43] Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
    Shin, Eunhae
    Lim, Dong Hui
    Han, Jisang
    Nam, Do-Hyun
    Park, Keunchil
    Ahn, Myung-Ju
    Kang, Won Ki
    Lee, Jeeyun
    Ahn, Jin Seok
    Lee, Se-Hoon
    Sun, Jong-Mu
    Jung, Hyun Ae
    Chung, Tae-Young
    [J]. BMC OPHTHALMOLOGY, 2020, 20 (01)
  • [44] JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options
    Stein, Brady L.
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 292 - 299
  • [45] Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
    Park, Sojung
    Lee, Sung Yong
    Kim, Dojin
    Sim, Yun Su
    Ryu, Jeong-Seon
    Choi, Juwhan
    Lee, Su Hwan
    Ryu, Yon Ju
    Lee, Jin Hwa
    Chang, Jung Hyun
    [J]. BMC CANCER, 2021, 21 (01)
  • [46] State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies
    Hanssens, Charlotte
    Mouna, Oumnia
    Meyers, Michel
    Hendlisz, Alain
    [J]. CURRENT OPINION IN ONCOLOGY, 2024, 36 (04) : 320 - 325
  • [47] Inhibiting fibroblast growth factor receptors in cancer - the next generation
    Schuler, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (10) : 1285 - 1286
  • [48] Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer
    Inokuchi, Mikito
    Fujimori, Yoshitaka
    Otsuki, Sho
    Sato, Yuya
    Nakagawa, Masatoshi
    Kojima, Kazuyuki
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2015, 2015
  • [49] Epidermal growth factor receptor (EGFR) inhibitors and derived treatments
    Dziadziuszko, R.
    Jassem, J.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 193 - 196
  • [50] Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
    Krook, Melanie A.
    Reeser, Julie W.
    Ernst, Gabrielle
    Barker, Hannah
    Wilberding, Max
    Li, Gary
    Chen, Hui-Zi
    Roychowdhury, Sameek
    [J]. BRITISH JOURNAL OF CANCER, 2021, 124 (05) : 880 - 892
12345